Enterprise & Clinical Partnerships
Direct access to Ali Shekh for hospital EHR integrations, DPDP compliance licensing, clinical trial co-development, wearable OEM SDK discussions, and investor inquiries.
⚡
24-hour response guarantee for clinical and enterprise inquiries —
direct executive review, no ticketing system.
👤 Executive Leadership
Custtre Intelligence Private Limited
🏆 Accreditations & Intellectual Property
🇮🇳
DPIIT Startup India Recognition
Certificate No: DIPP275973
Recognized
🔬
Indian Provisional Patent
Application No: 202621064913
Filed
✅
TRL-4 Functional Prototype
55/55 automated audit checks passed
TRL-4
🔐
NIST FIPS 203/204 PQC
Post-quantum cryptography implemented
Active
⚖️
DPDP Act 2023 Architecture
Section 6(1), 9, 12, 17 compliant by design
Compliant
🤝 Partnership Opportunities
🏥 Hospitals & Clinics
EHR integration, DPDP compliance APIs, FHIR R4 connectivity, clinical trial co-development.
⌚ Wearable OEM Manufacturers
BLE SDK integration, hardware key sealing middleware, 1.5–3.5% royalty licensing.
💰 Investors & Incubators
Seeking ₹1–10 Crore for TRL-5 → TRL-7. DPIIT GENESIS eligible — no equity dilution for grants.
🏛️ Government & ABDM
Rural PHC LoRaWAN deployments, NHA ABDM integration contracts, PPP infrastructure.
📩 Submit Your Inquiry
All inquiries are reviewed directly by Ali Shekh. Responses within 24 hours for clinical and enterprise matters.
A
Ali Shekh
Founder · Chairperson · Director · Lead PI · 51% Equity
M. Pharm (Pharmaceutics), specialist in pharmaceutical R&D, drug delivery kinetics, and deep-tech sequence algorithms. Lead inventor of Patent 202621064913. Heads software architecture, NIST PQC implementation, CYP450 clinical matrix, and regulatory compliance.
M. Pharm
Lead Inventor
PQC Architecture
A
Atifa
Co-Founder · Director · Operations Lead · 49% Equity
Journalism & Mass Communication background. Heads corporate operations, brand identity, investor communication, and DPDP compliance outreach. Drives go-to-market strategy and institutional partnership development across South Asia and GCC markets.
Operations
Brand & PR
Investor Relations
🤝 Leads Institutional Partnerships
Q1
Months 1–3: TRL-5 Hardening + CERT-In Audit
System optimisation, CERT-In cybersecurity auditing, ISO 27001 readiness, first clinical pilot outreach in Maharashtra.
Q2
Months 4–6: Hospital Pilots + ABDM Integration
Clinical pilot testing with hospital EHR systems. ABDM sandbox integration. Initial B2B API client onboarding.
Q3
Months 7–9: TRL-7 + VaaS Launch
Field-proven TRL-7 operational readiness. First paying B2B Vault-as-a-Service clients. LoRaWAN rural PHC nodes deployed.
Q4
By May 2027: Patent Complete + WIPO PCT
Complete Patent Specification filed. WIPO PCT international applications. Full commercial ABDM deployment. B2C app public release.
What is the B2B pricing model for hospital API integration?
▾
Hospital integrations use monthly/annual B2B SaaS subscriptions — API access to Vault-as-a-Service (VaaS) and Compliance-as-a-Service (CaaS), priced by monthly API call volume and patient record count. A 3-month pilot pricing period with reduced rates is available for the first integration. Contact Ali Shekh for a scoped pricing proposal within 24 hours.
Is Custtre compatible with our existing hospital EHR (Epic, Cerner, HealthOne)?
▾
Yes. The HL7 FHIR R4 Interoperability Converter translates local biomarker vectors into ABDM-compliant FHIR R4 JSON Observation payloads compatible with any FHIR-capable EHR. The FHIR ingest endpoint accepts standard Bundle resources with LOINC-coded observations. Integration timeline is typically 2–4 weeks for pilot connectivity.
What funding is Custtre seeking and on what terms?
▾
Currently seeking ₹1–10 Crore in seed funding for TRL-5 through TRL-7 milestones by May 2027. The company is eligible for the DPIIT GENESIS Deep-Tech Startup grant (up to ₹1 Crore, no equity dilution required). Equity-based seed investment proposals from healthcare-focused VCs and strategic corporate partners (hospital chains, insurance companies, wearable OEMs) are also being evaluated.
How do wearable OEM SDK royalties work?
▾
OEM manufacturers receive the BLE Direct-Streaming SDK and Hardware Key Sealing Middleware under a technology license agreement. Running royalties of 1.5%–3.5% apply on each unit shipped with the Custtre SDK embedded. Pre-integration technical documentation, CERT-In security certification materials, and dedicated engineering support are included in the license package.